Elimination Capacity Determines Outcome in Amatoxin Mushroom Poisoning-Induced Acute Liver Failure: A Globally Applicable Management Framework
The study reports a 98.8% transplant-free recovery rate among patients adhering to a new management protocol for amatoxin mushroom poisoning, highlighting the potential role of hydration and silibinin.
Where it sits
this study against the rest of the octreotide corpusSummary and findings
This study measured the outcomes of a management framework for amatoxin mushroom poisoning in a multicenter trial involving 99 patients. The intervention included sustained hydration, fasting plus octreotide, and intravenous silibinin. The study reported a transplant-free recovery rate of 98.8% among protocol-adherent patients.
Abstract
<h4>ABSTRACT</h4> Amatoxin mushroom poisoning causes acute liver failure; progression from cholera-like hypovolemia resolution to fatal multisystem collapse occurs unpredictably. We conducted a prospective single-arm multicenter trial (N=99) investigating proactive toxicokinetic-based management: sustained hydration for renal protection and clearance preservation, fasting plus octreotide to arrest enterohepatic circulation, and intravenous silibinin to block hepatic reuptake. Transplant-free recovery: 98.8% among protocol-adherent patients (n=86). Multivariable analysis: sustained hydration (P<0.001) and silibinin (P=0.003) predicted survival; octreotide reduced coagulopathy recovery time (P=0.01); N-acetylcysteine and charcoal achieved neither. Conventional MELD score–outcome relationships vanished in protocol-adherent patients, suggesting management modified the natural history. Poor outcomes followed a reproducible sequence—hydration withdrawal, lactate rebound, oliguric nephropathy, multisystem failure—kidney failure, not liver, precipitated collapse. These findings establish renal clearance preservation and gallbladder sequestration as central outcome determinants, supporting a globally applicable management framework substituting gallbladder drainage when silibinin is unavailable or likely to fail. ClinicalTrials.gov identifier: NCT00915681 .